Yuanzheng Zhang from Somerset, NJ, age 60

Associate Principal Scientist

view source

Location:

29 Brook St, Somerset, NJ 08873

Industry:

Pharmaceuticals

Work:

Merck
Associate Principal Scientist
Merck Jan 2010 - Feb 2014
Senior Scientist
Merck Aug 2005 - Dec 2009
Scientist Ii
University of Nebraska–Lincoln Jan 2001 - Jul 2005
Research Assistant Professor
University of Nebraska–Lincoln Dec 1997 - Dec 2000
Postdoc

Education:

Institute of Microbiology, Chinese Academy of Sciences 1994 - 1997
Doctorates, Doctor of Philosophy, Virology China Agricultural University 1990 - 1993
Masters, Microbiology Hebei University 1980 - 1984
Bachelors, Biochemistry

Skills:

Antibody Engineering
Cho Stable Cell Line Development
Mammalian Cell Culture
Cell Based Assay Development
Phage Display Antibody Library Construction
Molecular Cloning
Animal Vaccination and Downstream Serological Analysis
Assay Development
Virology
Molecular Biology
Vaccines
Elisa
Cell Culture
Protein Purification
Phage Display
Biotechnology
Monoclonal Antibodies
Antibodies
Cell Based Assays
Cell Biology
Protein Chemistry
Transfection
Western Blotting

Languages:

English

Yuanzheng Zhang

view source

Yuanzheng Zhang

view source

Yuanzheng Zhang Belle Mead, NJ

view source

Work:

G-Way Microwave, Inc

Apr 2009 to 2000
Senior Principal RF Design Engineer Wi-Tron, Inc

Apr 1996 to Apr 2009
Engineering Manager / Sr. RF Design Engineer Shanghai Telecommunication Company, Shanghai

Jul 1988 to Apr 1990
Electrical Engineer Bejing Radar Research Institute, Bejing China

Oct 1982 to Jun 1988
RF Design Engineer

Education:

City University of New York
New York, NY
Feb 1995 to Jun 1996
Master in Electrical Engineering University of Wuppertal
Jul 1990 to Mar 1994
Electrical Engineering Department National Defense University of Science and Technology
Sep 1978 to Aug 1982
Bachelor in Microwaves Technology

Us Patents

Lawsonia Intracellularis Vaccines
view source
US Patent:

20110200631, Aug 18, 2011
Filed:

Oct 21, 2009
Appl. No.:

13/125019
Inventors:

Mohamad A. Morsey - Elkhorn NE, US
Yuanzheng Zhang - Elkhorn NE, US
Qing Zhang - Short Hills NJ, US
Stephanie M. Cook - Elkhorn NE, US
International Classification:

A61K 39/02
C07K 14/195
G01N 33/566
C07H 21/00
C07H 21/04
A61P 31/04
A61P 37/04
US Classification:

4241901, 530350, 436501, 536 237
Abstract:

The present invention relates to polynucleotide sequences encoding novel polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant microorganisms comprising these sequences. Moreover, the invention relates to polypeptides encoded by these nucleotide sequences. The invention also relates to immunogenic compositions for prevention of infections and methods for the preparation of these immunogenic compositions. The invention also relates to diagnostic tests for the detection of DNA, the detection of antigens and detection of antibodies against

Pd-L1 Antibodies Binding Canine Pd-L1
view source
US Patent:

20220389114, Dec 8, 2022
Filed:

Aug 15, 2022
Appl. No.:

17/819745
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Jason Erskine - Omaha NE, US
Ian Tarpey - St. Ives, US
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
A61K 39/00
Abstract:

The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties. The present invention further relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes. The invention further discloses the use of the caninized anti-canine PD-LI antibodies of the present invention in the treatment of cancer in dogs.

Caninized Antibodies Against Canine Ctla-4
view source
US Patent:

20220251208, Aug 11, 2022
Filed:

Jul 15, 2020
Appl. No.:

17/626239
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Ian Tarpey - St. Ives, GB
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
Abstract:

The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4. The present invention further provides epitopes of canine CTLA-4 for caninized murine antibodies against canine CTLA-4.5 The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.

Caninized Antibodies To Human Ctla-4
view source
US Patent:

20220251209, Aug 11, 2022
Filed:

Jul 15, 2020
Appl. No.:

17/626242
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Ian Tarpey - St. Ives, GB
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
Abstract:

The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4. The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.

Caninized Antibodies
view source
US Patent:

20220204615, Jun 30, 2022
Filed:

Jan 12, 2022
Appl. No.:

17/573870
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Edison NJ, US
Ian Tarpey - St. Ives, GB
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
A61K 39/00
A61P 37/04
A61K 39/395
Abstract:

The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.

Antibodies To Canine Interleukin-4 Receptor Alpha
view source
US Patent:

20230053131, Feb 16, 2023
Filed:

Dec 18, 2020
Appl. No.:

17/784835
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
Abstract:

The present invention provides antibodies to canine IL-4 receptor alpha that have a highbinding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of canine IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Canine Interleukin-4 Receptor Alpha Antibodies
view source
US Patent:

20230044037, Feb 9, 2023
Filed:

Dec 18, 2020
Appl. No.:

17/785229
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
A61P 17/00
C12N 15/85
C12N 5/071
Abstract:

The present invention provides antibodies to canine IL-4 receptor alpha that have a high binding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Antibodies To Canine Interleukin-4 Receptor Alpha
view source
US Patent:

20210040223, Feb 11, 2021
Filed:

Oct 27, 2020
Appl. No.:

17/081188
Inventors:

- Madison NJ, US
Yuanzheng Zhang - Somerset NJ, US
Assignee:

Intervet Inc. - Madison NJ
International Classification:

C07K 16/28
Abstract:

The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor α. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.